The 2019 updated EULAR/ERA-EDTA guidelines for the management of lupus nephritis. Expert comments. Part I

The 2019 updated EULAR/ERA-EDTA guidelines for the management of lupus nephritis. Expert comments. Part II

Advances in rheumatology at the beginning of the 21st century

Adverse events that occurred in patients with rheumatoid arthritis during long-term follow-up

Alflutop Russian longitudinal multicenter observational study: use in patients with chronic back pain (message 3)

Alflutop Russian longitudinal multicentre observational study: preliminary results (message 1)

Analysis of 5-year clinical and radiological outcomes in patients with psoriatic arthritis observed as part of the Treat to target strategy. Preliminary data

Analysis of adherence to treatment in patients with rheumatoid arthritis

Analysis of the factors determining the development of postoperative pain in patients after knee and hip replacement surgery

Analysis of the mechanisms of development of neurorheumatological consequences of COVID-19 and the possibility of their pharmacological correction

ANALYSIS OF THE RESULTS OF TOFACITINIB THERAPY IN REAL CLINICAL PRACTICE ACCORDING TO THE ALL-RUSSIAN ARTHRITIS REGISTRY (OREL)

Antibodies to domain I β2 -glycoprotein 1 in patients with antiphospholipid syndrome and systemic lupus erythematosus

ANTIPHOSPHOLIPID SYNDROME AND SYSTEMIC LUPUS ERYTHEMATOSUS: WHAT DISEASE IS A CAUSE OF ORGAN DAMAGES?

Are the goals of therapy achievable in patients with rheumatoid arthritis receiving upadacitinib in real clinical practice?

Arthropathy associated with antitumor checkpoint inhibitors therapy: current understanding of the problem

Assessing the status of patients with rheumatoid arthritis: modern tendencies

Assessment of antiphospholipid antibodies using enzyme-linked immunosorbent assay and chemiluminescent method

Assessment of organization of medical care and drug provision for patients with rheumatic diseases, and the socioeconomic burden of these diseases in the Russian Federation

Assessment of the activity and organ damage in antiphospholipid syndrome

The association between genetic characteristics and treatment failure when switching from biologic disease-modifying antirheumatic drugs/Janus kinase inhibitors in patients with rheumatoid arthritis